Belite Bio, Inc (BLTE)
- Previous Close
38.38 - Open
38.50 - Bid 28.80 x 200
- Ask 40.17 x 100
- Day's Range
38.46 - 40.22 - 52 Week Range
11.00 - 48.60 - Volume
46,599 - Avg. Volume
48,704 - Market Cap (intraday)
1.183B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.19 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
56.50
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
www.belitebio.comRecent News: BLTE
Performance Overview: BLTE
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLTE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLTE
Valuation Measures
Market Cap
1.18B
Enterprise Value
1.10B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.08
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-35.11
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.50%
Return on Equity (ttm)
-47.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.63M
Diluted EPS (ttm)
-1.19
Balance Sheet and Cash Flow
Total Cash (mrq)
88.16M
Total Debt/Equity (mrq)
0.98%
Levered Free Cash Flow (ttm)
-15.3M